271 related articles for article (PubMed ID: 22879388)
1. EWS-FLI-1-targeted cytotoxic T-cell killing of multiple tumor types belonging to the Ewing sarcoma family of tumors.
Evans CH; Liu F; Porter RM; O'Sullivan RP; Merghoub T; Lunsford EP; Robichaud K; Van Valen F; Lessnick SL; Gebhardt MC; Wells JW
Clin Cancer Res; 2012 Oct; 18(19):5341-51. PubMed ID: 22879388
[TBL] [Abstract][Full Text] [Related]
2. EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model.
Peng W; Huang X; Yang D
Int Immunopharmacol; 2014 Aug; 21(2):336-41. PubMed ID: 24861249
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
4. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
[TBL] [Abstract][Full Text] [Related]
5. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
[TBL] [Abstract][Full Text] [Related]
6. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.
De Vito C; Riggi N; Suvà ML; Janiszewska M; Horlbeck J; Baumer K; Provero P; Stamenkovic I
PLoS One; 2011; 6(8):e23592. PubMed ID: 21853155
[TBL] [Abstract][Full Text] [Related]
7. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
8. [Construction of recombinant adenoviral vector containing gene of EWS-FLI1 and antitumor immunity of its modified dentritic cell in vitro].
Qu HY; Guo W; He XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Dec; 38(6):623-7. PubMed ID: 17173084
[TBL] [Abstract][Full Text] [Related]
9. Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening.
Grohar PJ; Woldemichael GM; Griffin LB; Mendoza A; Chen QR; Yeung C; Currier DG; Davis S; Khanna C; Khan J; McMahon JB; Helman LJ
J Natl Cancer Inst; 2011 Jun; 103(12):962-78. PubMed ID: 21653923
[TBL] [Abstract][Full Text] [Related]
10. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
11. EWS-FLI-1 expression triggers a Ewing's sarcoma initiation program in primary human mesenchymal stem cells.
Riggi N; Suvà ML; Suvà D; Cironi L; Provero P; Tercier S; Joseph JM; Stehle JC; Baumer K; Kindler V; Stamenkovic I
Cancer Res; 2008 Apr; 68(7):2176-85. PubMed ID: 18381423
[TBL] [Abstract][Full Text] [Related]
12. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
Joo J; Christensen L; Warner K; States L; Kang HG; Vo K; Lawlor ER; May WA
PLoS One; 2009 Oct; 4(10):e7608. PubMed ID: 19859563
[TBL] [Abstract][Full Text] [Related]
13. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
Prieur A; Tirode F; Cohen P; Delattre O
Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
[TBL] [Abstract][Full Text] [Related]
14. Ecteinascidin 743 interferes with the activity of EWS-FLI1 in Ewing sarcoma cells.
Grohar PJ; Griffin LB; Yeung C; Chen QR; Pommier Y; Khanna C; Khan J; Helman LJ
Neoplasia; 2011 Feb; 13(2):145-53. PubMed ID: 21403840
[TBL] [Abstract][Full Text] [Related]
15. PRAS40 is a functionally critical target for EWS repression in Ewing sarcoma.
Huang L; Nakai Y; Kuwahara I; Matsumoto K
Cancer Res; 2012 Mar; 72(5):1260-9. PubMed ID: 22241085
[TBL] [Abstract][Full Text] [Related]
16. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
[TBL] [Abstract][Full Text] [Related]
17. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
18. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
Theisen ER; Pishas KI; Saund RS; Lessnick SL
Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
[TBL] [Abstract][Full Text] [Related]
20. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
